TEM expands into radiology via Median partnership, adding AI lung screening to Pixel as FDA clearance and past deals boost imaging push.

Median Technologies’ eyonis (LCS) software, which recently gained FDA clearance, will be integrated into Tempus AI’s cardiac ...

Tempus AI, Inc. TEM recently announced a collaboration with Median Technologies to integrate Median’s proprietary eyonis LCS solution into the Tempus Pixel platform. The integration is expected to ...

Tempus AI launched its HRD-RNA algorithm, an AI-driven model for identifying Homologous Recombination Deficiency in cancer patients. The company also partnered with Median Technologies to integrate ...

Tempus HRD-RNA is an AI-driven, 1,660-gene logistic regression model designed to identify patients likely to respond to ...

Why do some patients respond to immuno-oncology drugs when others don’t? It’s one of many million-dollar questions in medicine that confound companies, researchers, and clinicians alike. And the ...

Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in TD Cowen's/Securities' 4th Annual Tools/Dx Revolution ...

It’s not often you hear someone in the workplace say they’re hoping to change the world. But at Tempus, it’s the norm. With a data-first mentality, Tempus hopes to improve outcomes in the health care ...

RNA sequencing provides a comprehensive view of biological information, offering deeper insights into disease mechanisms, including improved fusion detection. As a powerful tool in research and ...